# Second-Line Adjuvant Therapy With Nab-Paclitaxel Plus Gemcitabine Versus Oxaliplatin Plus Folinic Acid and Fluorouracil for Gemcitabine-Refractory Pancreatic Cancer After Curative Resection

> **NCT02506842** · PHASE3 · UNKNOWN · sponsor: **Fudan University** · enrollment: 300 (estimated)

## Conditions studied

- Stage ⅠA Pancreatic Cancer
- Stage ⅠB Pancreatic Cancer
- Stage ⅡA Pancreatic Cancer
- Stage ⅡB Pancreatic Cancer

## Interventions

- **DRUG:** nab-paclitaxel
- **DRUG:** gemcitabine
- **DRUG:** oxaliplatin
- **DRUG:** folinic acid
- **DRUG:** fluorouracil

## Key facts

- **NCT ID:** NCT02506842
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-06
- **Primary completion:** 2018-12
- **Final completion:** 2019-06
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2016-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02506842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02506842, "Second-Line Adjuvant Therapy With Nab-Paclitaxel Plus Gemcitabine Versus Oxaliplatin Plus Folinic Acid and Fluorouracil for Gemcitabine-Refractory Pancreatic Cancer After Curative Resection". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT02506842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*